Review Article

Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential

Table 1

ERP P300 studies in patients with AD.

StudyPopulation ()P300 latencyP300 amplitude

Ally et al., [54]HC (80)
AD (80)
Bennys et al., [47]HC (10)
MCI (20)
AD (30)
Caravaglios et al., [63]HC (16)
AD (21)
Cecchi et al., [105]HC (101)
Mild AD (103)
Cintra et al., [106]HC (14)
MCI (34)
AD (17)
(ApoE4+)
Frodl et al., [48]HC (26)
MCI (26)
AD (30)
Fruehwirt et al., [107]Mild AD (31)
Severe AD (32)
NA
Golob and Starr, [32]HC (12)
AD (10)
Hirata et al., [40]HC (12)
AD (26)
Jervis et al., [28, 108110]HC (9)
AD (9)
AD > HCHC = AD
Juckel et al., [111]HC (18)
AD (18)
Kraiuhin et al., [112]HC (100)
AD (25)
(but not statistically significant)NA
Lai et al., [53]HC (16)
AD (16)
Lee et al., [64]HC (31)
AD (31)
Marsh et al., [113]HC (17)
AD (18)
NA
O’Mahony et al., [114]HC (20)
AD (18)
NA
Papadaniil et al., [115]HC (21)
MCI (21)
AD (21)
(but not statistically significant)
Papaliagkas et al., [116]HC (30)
MCI (49)
AD (5)
AD, , AD
Papaliagkas, et al., [117]MCI (15)
AD (5)
Pedroso et al., [118]HC (30)
Mild AD (24)
NA
Pedroso et al., [119]HC (37)
AD (48)
Pokryszko-Dragan et al., [120]HC (13)
AD (13)
Polich et al., [121]HC (16)
AD (16)
Polich and Corey-Bloom, [30]HC (NA)
AD (NA)
Tachibana et al., [122]HC (15)
AD (15)
NA
Yamaguchi et al., [123]HC (16)
AD (16)

Abbreviations: AD: Alzheimer’s disease; ApoE4: apolipoprotein E4; HC: healthy control; MCI: mild cognitive impairment; and NA: not available.